These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25415817)

  • 21. A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.
    Jaisamrarn U; Chaovisitsaree S; Angsuwathana S; Nerapusee O
    Contraception; 2014 Nov; 90(5):535-41. PubMed ID: 25074072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations.
    Bäckström T; Hansson-Malmström Y; Lindhe BA; Cavalli-Björkman B; Nordenström S
    Contraception; 1992 Sep; 46(3):253-68. PubMed ID: 1451521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon).
    Ismail MT
    Malays J Reprod Health; 1994 Jun; 12(1):43-8. PubMed ID: 12320338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
    Vartiainen M; de Gezelle H; Broekmeulen CJ
    Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
    Larsson-Cohn U; Wallentin L; Zador G
    Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Desogestrel contraceptives: the perfect pill for lipids?].
    Laurendeau L
    Can Fam Physician; 1996 Jan; 42():62-71. PubMed ID: 8924815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of two monophase oral contraceptives with desogestrel].
    Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
    Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
    Van Trappen Y; Duvivier P; Thiery M; Van Kets H; Defoort P; Parewijck W; Derom R; Kermans G; Schoofs P
    Arzneimittelforschung; 1989 Jun; 39(6):717-9. PubMed ID: 2528355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
    Weijers MJ
    Clin Ther; 1982; 4(5):359-66. PubMed ID: 6461412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group.
    Contraception; 1994 Sep; 50(3):201-14. PubMed ID: 7805371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
    J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reciprocal coordination of a combination oral contraceptive containing desogestrel+ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells.
    Pandey H; Arjuman A; Roy KK; Chandra NC
    Contraception; 2011 Dec; 84(6):e43-9. PubMed ID: 22078205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of body composition during low-dose estrogen oral contraceptives treatment.
    Franchini M; Caruso C; Nigrelli S; Poggiali C
    Acta Eur Fertil; 1995; 26(2):69-73. PubMed ID: 9098463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.